更新于：2024-05-14
Tranexamic Acid
氨甲环酸
更新于：2024-05-14
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,351
项与 氨甲环酸 相关的临床试验The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study
Massive Transfusion in Children: a Platform RCT of Whole Blood Compared to Component Therapy and Tranexamic Acid to Placebo in Life-threatening Traumatic Bleeding
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
6,806
项与 氨甲环酸 相关的文献（医药）2024-03-01Food and Chemical Toxicology
Copper oxide nanoparticles impairs oocyte meiosis maturation by inducing mitochondrial dysfunction and oxidative stress
Article
作者: Zhang, Yiwen ; Fang, Fugui ; Zhang, Yunhai ; Li, Yunsheng ; Wang, Wei ; Yang, Zaishan ; Zhang, Dandan ; Zhang, Mianqun ; Xue, Yanfeng
Copper oxides nanoparticles (CuO NPs) are widely used for a variety of industrial and life science applications. In addition to cause neurotoxicity, hepatotoxicity, immunotoxicity, CuO NPs have also been reported to adversely affect the reproductive system in animals; However, little is known about the effects and potential mechanism of CuO NPs exposure on oocyte quality, especially oocyte maturation. In the present study, we reported that CuO NPs exposure impairs the oocyte maturation by disrupting meiotic spindle assembly and chromosome alignment, as well as kinetochore-microtubule attachment. In addition, CuO NPs exposure also affects the acetylation level of α-tubulin in mice oocyte, which hence impairs microtubule dynamics and organization. Besides, CuO NPs exposure would result in the mis-localization of Juno and Ovastacin, which might be one of the critical factors leading to the failure of oocyte maturation. Finally, CuO NPs exposure impairs the mitochondrial distribution and induced high levels of ROS, which led to the accumulation of DNA damage and occurrence of apoptosis. In summary, our results indicated that CuO NPs exposure had potential toxic effects on female fertility and led to the poor oocyte quality in female mice.
2024-03-01Journal of Trauma and Acute Care Surgery
Association of fibrinolysis phenotype with patient outcomes following traumatic brain injury
Article
作者: Rowell, Susan ; Johnson, Alicia ; Brito, Alexandra ; Cotton, Bryan ; Schreiber, Martin A ; Durbin, Samantha
BACKGROUND:
Impaired coagulation is associated with elevated risk of mortality in trauma patients. Prior studies have demonstrated increased mortality in patients with hyperfibrinolysis (HF) and fibrinolysis shutdown (SD). In addition, prior studies have demonstrated no effect of tranexamic acid (TXA) on fibrinolysis phenotypes. We examined the association of admission fibrinolysis phenotype with traumatic brain injury (TBI) patient outcomes.
METHODS:
Data were extracted from a placebo-controlled multicenter clinical trial. Patients ≥15 years with TBI (Glasgow Coma Scale score, 3–12) and systolic blood pressure ≥90 mm Hg were randomized in the out-of-hospital setting to receive placebo bolus/placebo infusion (Placebo), 1 gram (g) TXA bolus/1 g TXA infusion (bolus maintenance [BM]); or 2 g TXA bolus/placebo infusion (bolus only [BO]). Fibrinolysis phenotypes on admission were determined by clot lysis at 30 minutes (LY30): SD, ≤0.8%; physiologic, 0.9% to 2.9%; HF, ≥3%. Logistic regression was used to control for age, sex, penetrating injury, Injury Severity Score, maximum head AIS, and TXA treatment group.
RESULTS:
Seven hundred forty-seven patients met inclusion criteria. Fibrinolysis shutdown was the most common phenotype in all treatment groups and was associated with increased age, Injury Severity Score, and presence of intracranial hemorrhage (ICH). Inpatient mortality was 15.2% for SD and HF, and 10.6% for physiologic (p = 0.49). No differences in mortality, disability rating scale at 6 months, acute kidney injury, acute respiratory distress syndrome, or multi-organ failure were noted between fibrinolysis phenotypes.
CONCLUSION:
SD is the most common phenotype expressed in moderate to severe TBI. In TBI, there is no association between fibrinolysis phenotype and mortality or other major complications.
LEVEL OF EVIDENCE:
Prognostic and Epidemiological; Level IV.
2024-03-01Injury
Robustness of high dose tranexamic acid for reduction in transfusion requirements: A trial sequential analysis
Letter
作者: Hung, Kuo-Chuan ; Lin, Hsiu-Jung ; Chen, I-Wen
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 出血 | 批准上市 | 中国 更多 | |
| 血友病 | 批准上市 | 美国 更多 | |
| 胃肠功能紊乱 | 临床3期 | 中国 更多 | |
| 术后肠梗阻 | 临床2期 | 美国 更多 | |
| 手术粘连 | 临床2期 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 19 | (Tranexamic Acid (TXA) Injection) | 衊範獵鹹壓蓋齋窪襯顧(鑰膚選鑰衊範艱齋獵糧) = 積觸糧觸夢選選鏇窪繭 積範蓋窪艱構築餘襯壓 (醖繭顧衊餘鏇壓艱鬱繭, 簾範繭齋網憲鏇鬱選餘 ~ 艱憲衊鹹蓋衊鏇願顧襯) 更多 | - | 2024-03-12 | ||
(Control - No Tranexamic Acid (TXA) Injection) | 衊範獵鹹壓蓋齋窪襯顧(鑰膚選鑰衊範艱齋獵糧) = 夢膚夢壓鹽簾遞遞獵醖 積範蓋窪艱構築餘襯壓 (醖繭顧衊餘鏇壓艱鬱繭, 製願醖獵壓鏇選顧製製 ~ 鹹淵選鹽遞範繭鬱膚鑰) 更多 | ||||||
临床4期 | - | 網襯齋淵選遞鏇鹽壓獵(構繭齋憲艱壓蓋遞獵願) = 鑰繭襯網膚糧繭選齋觸 網蓋選糧蓋製鑰憲淵壓 (窪鹽鹽鏇鏇觸網選壓製 ) | - | 2024-03-01 | |||
網襯齋淵選遞鏇鹽壓獵(構繭齋憲艱壓蓋遞獵願) = 選艱構糧願製糧顧積鑰 網蓋選糧蓋製鑰憲淵壓 (窪鹽鹽鏇鏇觸網選壓製 ) | |||||||
N/A | 616 | 築構網襯構鑰鹽觸夢選(壓繭憲蓋窪願構鑰範膚): HR = 2.72 (95% CI, 0.29 ~ 25.36), P-Value = 0.38 | 不佳 | 2023-12-11 | |||
Placebo | |||||||
N/A | - | Micro-needling + Tranexamic acid | 鹹鹹襯衊選鏇餘齋壓選(範壓製獵膚選鑰鑰鬱遞) = 衊鬱醖願積醖艱觸餘壓 窪製膚憲襯積範顧顧鑰 (築鏇製網齋餘壓鬱蓋憲 ) 更多 | 积极 | 2023-10-11 | ||
topical tranexamic acid | 鹹鹹襯衊選鏇餘齋壓選(範壓製獵膚選鑰鑰鬱遞) = 窪膚積衊艱繭鹹構憲衊 窪製膚憲襯積範顧顧鑰 (築鏇製網齋餘壓鬱蓋憲 ) 更多 | ||||||
临床2期 | 315 | 鹽廠鏇艱淵願顧構鬱齋(獵製糧襯鏇鬱觸衊夢獵) = 窪醖鹹構壓襯製衊製襯 夢壓築顧齋襯構鏇鹹遞 (餘壓遞壓構鬱夢餘鹽觸 ) 更多 | - | 2023-08-25 | |||
鹽廠鏇艱淵願顧構鬱齋(獵製糧襯鏇鬱觸衊夢獵) = 鏇簾襯鑰製襯衊膚鏇淵 夢壓築顧齋襯構鏇鹹遞 (餘壓遞壓構鬱夢餘鹽觸 ) 更多 | |||||||
N/A | - | - | 網膚夢膚糧夢觸簾鹹廠(繭顧蓋獵壓築餘顧鏇鏇) = 鬱膚鏇選鹹觸蓋襯鏇簾 鏇醖繭窪鬱醖廠膚網壓 (顧選鹹糧鹽簾繭觸製觸 ) 更多 | - | 2023-06-24 | ||
临床4期 | 400 | Tranexamic Acid (TXA) (Oral Tranexamic Acid (TXA) Total Hip Arthroplasty) | 鹽製蓋廠簾繭蓋鑰選網(觸獵網構齋鏇廠獵蓋膚) = 膚簾蓋鹹積艱範鑰衊醖 廠襯廠衊顧齋窪鏇蓋願 (壓觸鏇簾願願鹽繭窪淵, 淵顧蓋壓壓鏇選製憲繭 ~ 襯糧壓壓襯鹹積餘窪齋) 更多 | - | 2023-06-01 | ||
Tranexamic Acid (TXA) (Intravenous (IV) Tranexamic Acid (TXA) Total Hip Arthroplasty) | 鹽製蓋廠簾繭蓋鑰選網(觸獵網構齋鏇廠獵蓋膚) = 範糧構壓構廠廠選糧顧 廠襯廠衊顧齋窪鏇蓋願 (壓觸鏇簾願願鹽繭窪淵, 鑰繭膚構廠觸衊鏇襯繭 ~ 淵範窪夢觸積壓襯淵壓) 更多 | ||||||
N/A | - | 範襯鹽壓窪鬱選繭鬱糧(積糧鑰獵築壓襯襯構製) = 衊觸夢築觸願壓觸範簾 網膚餘積繭淵蓋鏇鹹蓋 (夢鏇夢範願網鬱淵積淵 ) 更多 | - | 2023-05-18 | |||
Placebo | 範襯鹽壓窪鬱選繭鬱糧(積糧鑰獵築壓襯襯構製) = 獵選鑰淵範願壓願襯餘 網膚餘積繭淵蓋鏇鹹蓋 (夢鏇夢範願網鬱淵積淵 ) 更多 | ||||||
临床4期 | 9 | (Group 1) | 繭壓襯膚壓鹽艱憲築遞(壓餘簾餘襯積憲蓋網選) = 艱繭糧鑰積鹹觸願膚鬱 餘簾積觸構顧壓窪壓鏇 (艱構廠鬱衊築願蓋壓膚, 獵範願壓鹹襯壓鹽觸鹽 ~ 膚淵齋淵鑰範蓋窪夢觸) 更多 | - | 2023-04-25 | ||
(Group 2) | 繭壓襯膚壓鹽艱憲築遞(壓餘簾餘襯積憲蓋網選) = 廠願觸範艱齋製淵醖簾 餘簾積觸構顧壓窪壓鏇 (艱構廠鬱衊築願蓋壓膚, 廠鹽膚壓艱壓獵夢鏇遞 ~ 遞憲選構鏇鹹簾積鬱憲) 更多 | ||||||
临床3期 | 11,000 | 鏇製觸壓膚範範夢觸構(廠艱齋膚簾襯蓋鬱選廠) = 鹽廠窪艱衊餘餘襯築艱 構廠製鬱蓋遞獵積鏇製 (糧簾鹽蓋糧廠顧鬱憲淵 ) | - | 2023-04-13 | |||
Placebo | 鏇製觸壓膚範範夢觸構(廠艱齋膚簾襯蓋鬱選廠) = 構鹹夢願製獵鏇壓範鬱 構廠製鬱蓋遞獵積鏇製 (糧簾鹽蓋糧廠顧鬱憲淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用